Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Study completedNCT05747924
What this trial is testing

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Who this might be right for
FSHDFSHD1FSHD2+24 more
Avidity Biosciences, Inc. 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06547216
What this trial is testing

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Who this might be right for
FSHDFSHD1FSHD2+24 more
Avidity Biosciences, Inc. 84
Large-scale testing (Phase 3)Looking for participantsNCT07038200
What this trial is testing

Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Who this might be right for
Facioscapulohumeral Muscular DystrophyFSHDFSHD - Facioscapulohumeral Muscular Dystrophy+14 more
Avidity Biosciences, Inc. 200
Not applicableStudy completedNCT04907162
What this trial is testing

Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders

Who this might be right for
Pompe Disease (Late-onset)Myotonic Dystrophy Type 1 (DM1)Myotonic Dystrophy Type 2+4 more
LMU Klinikum 82
Large-scale testing (Phase 3)Ended earlyNCT05397470
What this trial is testing

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Who this might be right for
Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics 260
Not applicableLooking for participantsNCT04369209
What this trial is testing

A Registered Cohort Study on FSHD1

Who this might be right for
Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
Ning Wang, MD., PhD. 1,000